Programmable Magnetic Navigation of Gelatin Microrobots Enhances AB4 Delivery to Inflamed Lung Epithelium

Sepsis-induced acute lung injury (SALI) is characterized by dysregulated inflammation with limited therapeutic options. Although Anemoside B4 (AB4) exhibits anti-inflammatory properties, its clinical application is hindered by poor bioavailability. To address this limitation, we developed magnetically guided gelatin microrobots (MG-AB4) for targeted AB4 delivery. The MG-AB4 system consists of a Fe3O4-loaded gelatin shell for enabling precise magnetic navigation (velocity: 110 μm/s), an AB4 core for rapid drug release which is advantageous for acute inflammatory responses, and surface modifications to enhance cellular uptake. Compared with free AB4, MG-AB4 significantly suppressed key inflammatory cytokines (Interleukin-6 (IL-6), Interleukin-1 beta (IL-1β), Tumor necrosis factor-alpha (TNF-α); p < 0.01), inhibited NF-κB activation (p < 0.01), and improved cell viability in an inflammatory model (p < 0.05). This study demonstrates that magnetically guided AB4 delivery using rapidly releasing microrobots is a promising strategy for SALI treatment, wherein the synergy of targeted delivery and potent anti-inflammatory action may effectively mitigate disease progression.